6CM
IMDX

683 Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History

683 Capital Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$95.1K Sell
29,000
-48,204
-62% -$280K 0.01% 221
2025
Q4 		$579K Buy
+77,204
New +$436K 0.03% 185

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

683 Capital Management's IMDX Position: Q1 2026 in Review

683 Capital Management reduced its Insight Molecular Diagnostics (IMDX) stake by 62% in Q1 2026, selling an estimated $280K and leaving 29,000 shares worth $95.1K. The position accounts for 0.01% of the portfolio, ranked #221.

683 Capital Management first reported a position in IMDX in Q4 2025 and has held it in 2 quarters since. The position peaked at $579K in Q4 2025. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • 683 Capital Management held 29,000 shares of Insight Molecular Diagnostics worth $95.1K as of Q1 2026.
  • 683 Capital Management sold 48,204 Insight Molecular Diagnostics shares in Q1 2026, an estimated $280K.
  • Insight Molecular Diagnostics made up 0.01% of 683 Capital Management's portfolio in Q1 2026, its #221 holding.
  • 683 Capital Management first reported a position in Insight Molecular Diagnostics in Q4 2025 and has held it in 2 quarters since.
  • 683 Capital Management's Insight Molecular Diagnostics position peaked at $579K in Q4 2025.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.